APO Research
Talk to an analyst

APO RESEARCH · REPORT

CGRP Monoclonal Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CGRP Monoclonal Antibodies Market Outlook and Growth Opportunities 2026

27 December 2025196 pages

Choose your research edition.

Industry ResearchCGRP Monoclonal Antibodies Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal CGRP Monoclonal Antibodies Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal CGRP Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CGRP Monoclonal Antibodies Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal CGRP Monoclonal Antibodies Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global CGRP Monoclonal Antibodies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CGRP Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CGRP Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CGRP Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CGRP Monoclonal Antibodies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CGRP Monoclonal Antibodies market include Alder Therapeutics, Amgen Inc., Daiichi Sankyo Co., Ltd., Pfizer Inc., Lilly Inc., Lundbeck, Novartis International AG and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CGRP Monoclonal Antibodies market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CGRP Monoclonal Antibodies and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CGRP Monoclonal Antibodies revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CGRP Monoclonal Antibodies market.

CGRP Monoclonal Antibodies Segment by Company

Alder Therapeutics

Amgen Inc.

Daiichi Sankyo Co., Ltd.

Pfizer Inc.

Lilly Inc.

Lundbeck

Novartis International AG

Teva

CGRP Monoclonal Antibodies Segment by Type

Erenumab

Fremanezumab

Galcanezumab

Eptinezumab

CGRP Monoclonal Antibodies Segment by Application

Specialty Clinic

Hospital

Others

CGRP Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global CGRP Monoclonal Antibodies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CGRP Monoclonal Antibodies key companies, revenue, market share, and recent developments.

3. To split the CGRP Monoclonal Antibodies breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CGRP Monoclonal Antibodies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CGRP Monoclonal Antibodies significant trends, drivers, influence factors in global and regions.

6. To analyze CGRP Monoclonal Antibodies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGRP Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CGRP Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGRP Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CGRP Monoclonal Antibodies industry.

Chapter 3: Detailed analysis of CGRP Monoclonal Antibodies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CGRP Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CGRP Monoclonal Antibodies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CGRP Monoclonal Antibodies Industry Trends Table 2. CGRP Monoclonal Antibodies Industry Drivers Table 3. CGRP Monoclonal Antibodies Industry Opportunities and Challenges Table 4. CGRP Monoclonal Antibodies Industry Restraints Table 5. Global CGRP Monoclonal Antibodies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CGRP Monoclonal Antibodies Revenue Share by Company (2021-2026) Table 7. Global CGRP Monoclonal Antibodies Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CGRP Monoclonal Antibodies Key Company Manufacturing Base & Headquarters Table 9. Global CGRP Monoclonal Antibodies Company, Product Type & Application Table 10. Global CGRP Monoclonal Antibodies Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CGRP Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Erenumab Table 15. Significant Companies of Fremanezumab Table 16. Significant Companies of Galcanezumab Table 17. Significant Companies of Eptinezumab Table 18. Global CGRP Monoclonal Antibodies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global CGRP Monoclonal Antibodies Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global CGRP Monoclonal Antibodies Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global CGRP Monoclonal Antibodies Sales Value Share by Type (2021-2026) Table 22. Global CGRP Monoclonal Antibodies Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Specialty Clinic Table 24. Significant Companies of Hospital Table 25. Significant Companies of Others Table 26. Global CGRP Monoclonal Antibodies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global CGRP Monoclonal Antibodies Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global CGRP Monoclonal Antibodies Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global CGRP Monoclonal Antibodies Sales Value Share by Application (2021-2026) Table 30. Global CGRP Monoclonal Antibodies Sales Value Share by Application (2027-2032) Table 31. Global CGRP Monoclonal Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global CGRP Monoclonal Antibodies Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global CGRP Monoclonal Antibodies Sales Value Share by Region (2021-2026) Table 34. Global CGRP Monoclonal Antibodies Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global CGRP Monoclonal Antibodies Sales Value Share by Region (2027-2032) Table 36. Global CGRP Monoclonal Antibodies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global CGRP Monoclonal Antibodies Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global CGRP Monoclonal Antibodies Sales Value Market Share by Country (2021-2026) Table 39. Global CGRP Monoclonal Antibodies Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global CGRP Monoclonal Antibodies Sales Value Market Share by Country (2027-2032) Table 41. Alder Therapeutics Company Information Table 42. Alder Therapeutics Business Overview Table 43. Alder Therapeutics CGRP Monoclonal Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Alder Therapeutics CGRP Monoclonal Antibodies Product Portfolio Table 45. Alder Therapeutics Recent Development Table 46. Amgen Inc. Company Information Table 47. Amgen Inc. Business Overview Table 48. Amgen Inc. CGRP Monoclonal Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Amgen Inc. CGRP Monoclonal Antibodies Product Portfolio Table 50. Amgen Inc. Recent Development Table 51. Daiichi Sankyo Co., Ltd. Company Information Table 52. Daiichi Sankyo Co., Ltd. Business Overview Table 53. Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Product Portfolio Table 55. Daiichi Sankyo Co., Ltd. Recent Development Table 56. Pfizer Inc. Company Information Table 57. Pfizer Inc. Business Overview Table 58. Pfizer Inc. CGRP Monoclonal Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Pfizer Inc. CGRP Monoclonal Antibodies Product Portfolio Table 60. Pfizer Inc. Recent Development Table 61. Lilly Inc. Company Information Table 62. Lilly Inc. Business Overview Table 63. Lilly Inc. CGRP Monoclonal Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Lilly Inc. CGRP Monoclonal Antibodies Product Portfolio Table 65. Lilly Inc. Recent Development Table 66. Lundbeck Company Information Table 67. Lundbeck Business Overview Table 68. Lundbeck CGRP Monoclonal Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Lundbeck CGRP Monoclonal Antibodies Product Portfolio Table 70. Lundbeck Recent Development Table 71. Novartis International AG Company Information Table 72. Novartis International AG Business Overview Table 73. Novartis International AG CGRP Monoclonal Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Novartis International AG CGRP Monoclonal Antibodies Product Portfolio Table 75. Novartis International AG Recent Development Table 76. Teva Company Information Table 77. Teva Business Overview Table 78. Teva CGRP Monoclonal Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Teva CGRP Monoclonal Antibodies Product Portfolio Table 80. Teva Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. CGRP Monoclonal Antibodies Product Image Figure 2. Global CGRP Monoclonal Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CGRP Monoclonal Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global CGRP Monoclonal Antibodies Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Erenumab Image Figure 8. Fremanezumab Image Figure 9. Galcanezumab Image Figure 10. Eptinezumab Image Figure 11. Global CGRP Monoclonal Antibodies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global CGRP Monoclonal Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global CGRP Monoclonal Antibodies Sales Value Share by Type (2021-2032) Figure 14. Specialty Clinic Image Figure 15. Hospital Image Figure 16. Others Image Figure 17. Global CGRP Monoclonal Antibodies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global CGRP Monoclonal Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global CGRP Monoclonal Antibodies Sales Value Share by Application (2021-2032) Figure 20. Global CGRP Monoclonal Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global CGRP Monoclonal Antibodies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America CGRP Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 23. North America CGRP Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe CGRP Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 25. Europe CGRP Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific CGRP Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific CGRP Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America CGRP Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 29. South America CGRP Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa CGRP Monoclonal Antibodies Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa CGRP Monoclonal Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Erenumab
  • Fremanezumab
  • Galcanezumab
  • Eptinezumab
Applications
  • Specialty Clinic
  • Hospital
  • Others
Companies covered
  • Alder Therapeutics
  • Amgen Inc.
  • Daiichi Sankyo Co., Ltd.
  • Pfizer Inc.
  • Lilly Inc.
  • Lundbeck
  • Novartis International AG
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CGRP Monoclonal Antibodies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CGRP Monoclonal Antibodies Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CGRP Monoclonal Antibodies Market Dynamics
  1. 2.1 CGRP Monoclonal Antibodies Industry Trends
  2. 2.2 CGRP Monoclonal Antibodies Industry Drivers
  3. 2.3 CGRP Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 CGRP Monoclonal Antibodies Industry Restraints
3 CGRP Monoclonal Antibodies Market by Company
  1. 3.1 Global CGRP Monoclonal Antibodies Company Revenue Ranking in 2025
  2. 3.2 Global CGRP Monoclonal Antibodies Revenue by Company (2021-2026)
  3. 3.3 Global CGRP Monoclonal Antibodies Company Ranking (2024-2026)
  4. 3.4 Global CGRP Monoclonal Antibodies Company Manufacturing Base and Headquarters
  5. 3.5 Global CGRP Monoclonal Antibodies Company Product Type and Application
  6. 3.6 Global CGRP Monoclonal Antibodies Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CGRP Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CGRP Monoclonal Antibodies Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CGRP Monoclonal Antibodies Market by Type
  1. 4.1 CGRP Monoclonal Antibodies Type Introduction
  2. 4.1.1 Erenumab
  3. 4.1.2 Fremanezumab
  4. 4.1.3 Galcanezumab
  5. 4.1.4 Eptinezumab
  6. 4.2 Global CGRP Monoclonal Antibodies Sales Value by Type
  7. 4.2.1 Global CGRP Monoclonal Antibodies Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global CGRP Monoclonal Antibodies Sales Value by Type (2021-2032)
  9. 4.2.3 Global CGRP Monoclonal Antibodies Sales Value Share by Type (2021-2032)
5 CGRP Monoclonal Antibodies Market by Application
  1. 5.1 CGRP Monoclonal Antibodies Application Introduction
  2. 5.1.1 Specialty Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global CGRP Monoclonal Antibodies Sales Value by Application
  6. 5.2.1 Global CGRP Monoclonal Antibodies Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global CGRP Monoclonal Antibodies Sales Value by Application (2021-2032)
  8. 5.2.3 Global CGRP Monoclonal Antibodies Sales Value Share by Application (2021-2032)
6 CGRP Monoclonal Antibodies Regional Value Analysis
  1. 6.1 Global CGRP Monoclonal Antibodies Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CGRP Monoclonal Antibodies Sales Value by Region (2021-2032)
  3. 6.2.1 Global CGRP Monoclonal Antibodies Sales Value by Region: 2021-2026
  4. 6.2.2 Global CGRP Monoclonal Antibodies Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CGRP Monoclonal Antibodies Sales Value (2021-2032)
  7. 6.3.2 North America CGRP Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CGRP Monoclonal Antibodies Sales Value (2021-2032)
  10. 6.4.2 Europe CGRP Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CGRP Monoclonal Antibodies Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CGRP Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CGRP Monoclonal Antibodies Sales Value (2021-2032)
  16. 6.6.2 South America CGRP Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CGRP Monoclonal Antibodies Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CGRP Monoclonal Antibodies Sales Value Share by Country, 2025 VS 2032
7 CGRP Monoclonal Antibodies Country-level Value Analysis
  1. 7.1 Global CGRP Monoclonal Antibodies Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CGRP Monoclonal Antibodies Sales Value by Country (2021-2032)
  3. 7.2.1 Global CGRP Monoclonal Antibodies Sales Value by Country (2021-2026)
  4. 7.2.2 Global CGRP Monoclonal Antibodies Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CGRP Monoclonal Antibodies Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CGRP Monoclonal Antibodies Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CGRP Monoclonal Antibodies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alder Therapeutics
  2. 8.1.1 Alder Therapeutics Company Information
  3. 8.1.2 Alder Therapeutics Business Overview
  4. 8.1.3 Alder Therapeutics CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alder Therapeutics CGRP Monoclonal Antibodies Product Portfolio
  6. 8.1.5 Alder Therapeutics Recent Developments
  7. 8.2 Amgen Inc.
  8. 8.2.1 Amgen Inc. Company Information
  9. 8.2.2 Amgen Inc. Business Overview
  10. 8.2.3 Amgen Inc. CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Inc. CGRP Monoclonal Antibodies Product Portfolio
  12. 8.2.5 Amgen Inc. Recent Developments
  13. 8.3 Daiichi Sankyo Co., Ltd.
  14. 8.3.1 Daiichi Sankyo Co., Ltd. Company Information
  15. 8.3.2 Daiichi Sankyo Co., Ltd. Business Overview
  16. 8.3.3 Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Daiichi Sankyo Co., Ltd. CGRP Monoclonal Antibodies Product Portfolio
  18. 8.3.5 Daiichi Sankyo Co., Ltd. Recent Developments
  19. 8.4 Pfizer Inc.
  20. 8.4.1 Pfizer Inc. Company Information
  21. 8.4.2 Pfizer Inc. Business Overview
  22. 8.4.3 Pfizer Inc. CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc. CGRP Monoclonal Antibodies Product Portfolio
  24. 8.4.5 Pfizer Inc. Recent Developments
  25. 8.5 Lilly Inc.
  26. 8.5.1 Lilly Inc. Company Information
  27. 8.5.2 Lilly Inc. Business Overview
  28. 8.5.3 Lilly Inc. CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lilly Inc. CGRP Monoclonal Antibodies Product Portfolio
  30. 8.5.5 Lilly Inc. Recent Developments
  31. 8.6 Lundbeck
  32. 8.6.1 Lundbeck Company Information
  33. 8.6.2 Lundbeck Business Overview
  34. 8.6.3 Lundbeck CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lundbeck CGRP Monoclonal Antibodies Product Portfolio
  36. 8.6.5 Lundbeck Recent Developments
  37. 8.7 Novartis International AG
  38. 8.7.1 Novartis International AG Company Information
  39. 8.7.2 Novartis International AG Business Overview
  40. 8.7.3 Novartis International AG CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis International AG CGRP Monoclonal Antibodies Product Portfolio
  42. 8.7.5 Novartis International AG Recent Developments
  43. 8.8 Teva
  44. 8.8.1 Teva Company Information
  45. 8.8.2 Teva Business Overview
  46. 8.8.3 Teva CGRP Monoclonal Antibodies Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teva CGRP Monoclonal Antibodies Product Portfolio
  48. 8.8.5 Teva Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst